Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Real-world Study
Conclusions:
Use of paclitaxel/ramucirumab combination beyond first-line treatment is associated with improved OS among patients with metastatic gastric/lower esophageal adenocarcinoma in this real-world study. Further work is needed to reduce disparity in our health care system between individuals living in rural versus urban areas.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
More News: Adenocarcinoma | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Health Management | Palliative | Rural Health | Study